Drugs that are used to treat patients with human immunodeficiencyvirus (HIV) infection are classified according to their target.The first ones to be developed were nucleoside reverse-transcriptaseinhibitors (NRTIs), which lead to premature termination of thenascent DNA chain, and nonnucleoside reverse-transcriptase inhibitors(NNRTIs), which bind and inhibit reverse transcriptase. Theviral protease inhibitors were next. NRTIs, NNRTIs, and proteaseinhibitors remain the staples of highly active antiretroviraltherapy, but other targets, such as the CCR5 receptor, the fusionpeptide, and viral integrase, have recently yielded promisingmolecules.
At this time, eradication of HIV is impossible. Rebound inevitablyfollows . . . [Full Text of this Article]
Source Information
From the Department of Infectious Diseases, Geneva University Hospital, Geneva.
Related Letters:
Initial Treatment of HIV-1 Infection
Schulz T. R., Street A. C., Nicastri E., Narciso P., Andreoni M., Riddler S. A., Haubrich R., Mellors J. W.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:970-971, Aug 28, 2008.
Correspondence
This article has been cited by other articles:
Schulz, T. R., Street, A. C., Nicastri, E., Narciso, P., Andreoni, M., Riddler, S. A., Haubrich, R., Mellors, J. W.
(2008). Initial treatment of HIV-1 infection.. NEJM
359: 970-971
[Full Text]
(2008). Seeking the Best HIV Drugs. JWatch General
2008: 2-2
[Full Text]
Previous
